Press release centre
Past Press Releases - Molecular Partners
July 1, 2014 Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program. More
January 17, 2013 Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its ... Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema More
May 31, 2012 Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as CMO Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer. More
June 29, 2010 Molecular Partners appoints Göran Ando as independent non executive board member Molecular Partners AG, the global leader in the development of DARPins as unique next generation protein therapeutics, announced today the appointment of Dr Göran Ando as independent non-executive member of the board of directors. More
December 15, 2009 Molecular Partners secures CHF 46 million in Series B financing led by Essex Woodlands ... Molecular Partners secures CHF 46 million in Series B financing led by Essex Woodlands Health Ventures More
May 14, 2009 Molecular Partners AG reaches all research milestones in collaboration Molecular Partners AG, pioneer in the development of DARPins, a novel class of therapeutic proteins, announced today that it has reached all milestones of the research phase earlier than anticipated in its ongoing collaboration with Centocor Research & Development, Inc. More
January 15, 2008 Molecular Partners AG collaborates with Centocor Research & Development, Inc. Molecular Partners AG today announced a collaborative research and license agreement with Centocor Research & Development, Inc. More
November 8, 2007 Molecular Partners appoints Jörn Aldag as chairman of the board Molecular Partners AG, a pioneer in the development of a novel class of therapeutic proteins termed DARPins, has announced the appointment of Jörn Aldag as President to the Board. More |